Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

DehydraTECH-semaglutide

Other · Agonist of GLP-1 receptor (GIPR) · developed by Lexaria Bioscience

Phase 1 Most advanced trial (none active)

LEXX Developer

1 Registered trials

What is DehydraTECH-semaglutide?

DehydraTECH-semaglutide is an oral formulation of semaglutide delivered via DehydraTECH technology. It is being studied in type 2 diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Targets: GLP-1 receptor (GIPR)
Mechanism: Agonist of GLP-1 receptor (GIPR)
Therapy area: Endocrine
Developer: Lexaria Bioscience Corp. (LEXX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06648031	Phase 1	Type2diabetes	Completed	LEXX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Type2diabetes

Other drugs acting on GIPR

Tirzepatide FDA approved LY3537021 Phase 2 Maridebart Cafraglutide Phase 3 VK2735 Investigational

More from Lexaria Bioscience

DehydraTECH-CBD Phase 1

Sources

ClinicalTrials.gov NCT06648031

Updated Oct 3, 2026. Something wrong or missing? Report it on the LEXX page.

Follow LEXX, the company behind DehydraTECH-semaglutide

See LEXX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LEXX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z